Utility of novel coronary artery disease biomarker algorithm in modifying physician adherence presented at 20th World Congress on Heart Disease
The PULS Cardiac Test™ identifies asymptomatic patients at risk of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom are missed by conventional evaluation
A currently unmet need in clinical cardiology is the identification of individuals with active yet undetected sub-clinical disease, who are at risk of experiencing a coronary event, and for whom early intervention can help- “the vulnerable patient”. Initial coronary artery disease (CAD) presentation for most of these patients is acute coronary syndrome (ACS) from rupture of non-obstructive plaque.
Screening for ACS risk remains a challenge; traditional risk factors and standard noninvasive testing predict only 60-65% of events. In this study, we examined whether providing physicians with a novel CAD predictive algorithm would impact their management of patients to conform more appropriately to established guidelines.
Dr. Douglas Harrington, Clinical Professor, USC Keck School of Medicine, presented “Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline based therapy” at the 20th Annual World Congress on Heart Disease conference on July 25th in Vancouver, British Columbia.
“Too many individuals are dying or on disability because of this disease – which is 80% preventable. As such, there is a great need to identify these vulnerable patients before an unstable cardiac lesion rupture causes a cardiac event,” says Dr. Douglas Harrington. “We believe this is an important step forward in combating the world’s deadliest disease.”
Dr. Harrington stated that the study indicates that physicians will appropriately use biomarker data and algorithmic scores to guide therapy when provided with the additional biomarker information that characterizes endothelial injury and progression, and will implement therapeutic plans in agreement with guidelines.
Unlike current clinical assessments, the PULS Cardiac Test measures 9 biomarkers that are involved in the development and progression of unstable cardiac lesions or vulnerable plaque providing a more complete picture of a patients cardiac health,” states Dr. Harrington.
Dr. Harrington is spoke to the World Congress on Heart Disease attendees on Saturday, July 25, 2015 at the Hyatt Regency Hotel in downtown Vancouver.